-
-
- CHAPTER 1 ABOUT THIS PROFILE
-
Executive summary
-
Quarterly news update
-
Company introduction
-
Company sales
-
Company financials
-
Key products and competitors
-
Data sourcing
-
Sales data
-
Analyst consensus
- CHAPTER 2 EXECUTIVE SUMMARY
-
Key findings
-
Prescription pharmaceutical sales performance, 2001-13
-
Financial performance, 2001-13
-
Financial performance, 2001-13
-
Gilead Science: PharmaVitae forecasts at a glance
-
Strategic insight
-
Gilead - the evolution of the HIV therapy leader
-
Atripla forecast to propel Gilead to the top
-
Gilead's leading three HIV therapies do not exhibit 'classic' life cycles
-
Gilead looks outside to diversify and spread risk
-
SWOT analysis
-
Strengths
-
Weaknesses
-
Opportunities
-
Threats
- CHAPTER 3 QUARTERLY NEWS UPDATE
-
Product developments
-
Deals and alliances
-
Product deals
-
Technology deals
-
M&A activity
-
Company announcements
-
Future product milestones
- CHAPTER 4 COMPANY INTRODUCTION
-
Key findings
-
Background
-
Key corporate developments
-
M&A history
-
Myogen
-
Corus
-
Raylo Chemicals
-
M&A strategy
- CHAPTER 5 COMPANY SALES
-
Key findings
-
Prescription pharmaceutical sales and growth rate analysis, 2001-13
-
Product analysis
-
Product analysis, 2001-07
-
Product analysis, 2007-13
-
Therapy area analysis
-
Therapy area analysis, 2001-07
-
Therapy area analysis, 2007-13
-
Therapy area focus, 2001-13
-
Geographic analysis
-
Geographic analysis, 2001-07
-
Geographic analysis, 2001-07
-
Geographic analysis, 2007-13
-
Geographic focus, 2001-13
-
Launch/core/expiry analysis
-
Explanation of launch/core/expiry analysis
-
Launch analysis, 2007-13
-
Core analysis, 2007-13
-
Expiry analysis, 2007-13
-
Launch/core/expiry configuration, 2007-13
-
Molecule type analysis
-
Molecule type analysis, 2001-07
-
Molecule type analysis, 2001-07
-
Molecule type analysis, 2007-13
-
Externalization analysis
-
Externalization analysis, 2001-07
-
Externalization analysis, 2007-13
- CHAPTER 6 COMPANY FINANCIALS
-
Key findings
-
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07
-
Financial statements, 2001-07
-
Profit and loss account, 2001-07
-
Balance sheet, 2001-07
-
Operating costs and profit analysis
-
Operating costs and profit analysis, 2001-07
-
Operating cost ratio and profit margin analysis, 2001-07
-
Operating cost ratio and profit margin analysis, 2007-13
-
Operating costs and profit analysis, 2007-13
-
Return on capital employed analysis
-
Capital employed analysis, 2001-07
-
Capital employed analysis, 2001-07
-
Return on capital employed (RoCE) analysis, 2001-07
- CHAPTER 7 KEY PRODUCTS AND COMPETITORS
-
Key findings
-
Overview
-
